• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Encouraging Signals from the Justice Department on Safe Consumption Sites
Jeffrey A. SingerThe Associated Pressreports the U.S. Department of Justice announced it is “evaluating supervised consumption sites, including discussions with state and local regulators about appropriate guardrails for such sites, as part of an overall approach to harm reduction and public safety.” This is welcome news.As I explained in a 2019Cato Policy Analysis, safe consumption sites (also called “safe injection sites” and “overdose prevention sites”) have established a track record of saving lives and preventing the spread of HIV, hepatitis, and other infectious diseases since the late 1980...
Source: Cato-at-liberty - February 8, 2022 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs

Safe Consumption Sites Reduce The Stress on Hospitals and Emergency Departments
Jeffrey A. SingerI wrote previously about a secret safe consumption site that has been providing services in an undisclosed location since 2014. The harm reduction organization operating it has agreed to share its data with researchers providing the researchers keep the name and location of the site confidential. This is because the federal “Crack House Statute” makes safe consumption sites illegal in the U.S.The researchers published theirfirst report in 2017. They reported that in the site ’s first 2 years of operation there were 2,574 injections among more than 100 participants, most of whom were injecti...
Source: Cato-at-liberty - January 15, 2022 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs

NIH and Other Public Private Partnerships to Research Treatments for Multiple Diseases
Over the past few weeks, the National Institutes of Health (NIH) has made a number of important announcements regarding collaborations with industry as well as the funding of several new research initiatives. Below is a summary of these stories. NIH Partners With Eli Lilly and Others on Rare Diseases FierceBiotechResearch reported that NIH selected four (4) new preclinical drug development studies to uncover new therapies for rare diseases. The projects will be funded through the Therapeutics for Rare and Neglected Diseases (TRND) program under NIH's National Center for Advancing Translational Sciences, NCATS, which ...
Source: Policy and Medicine - October 4, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs